Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 3/2012

01-09-2012 | Metabolic Complications and Comorbidity (JM Kilby, Section Editor)

HIV-Specific Immune Dysregulation and Atherosclerosis

Authors: Markella V. Zanni, Steven K. Grinspoon

Published in: Current HIV/AIDS Reports | Issue 3/2012

Login to get access

Abstract

HIV + patients face a heightened risk of cardiovascular disease (CVD), which cannot be fully explained by traditional risk factors or antiretroviral therapy (ART)-related cardiotoxicity. Increasing evidence suggests a significant contribution of HIV-specific immune dysregulation to atherosclerosis. HIV-specific immune dysregulation may have the following atherogenic effects: 1) activation of endothelial and immune cells; 2) enhancement of the percentage of circulating atherogenic immune cell subsets; and 3) modification of lipid function. Efforts are underway to link immune dysregulation markers with validated CVD endpoints and to identify genetic predispositions for HIV-induced atherogenesis. Moreover, immune suppressants are under evaluation in HIV + patients to attempt modification of immune-mediated CVD risk. Taken together, these studies will enhance understanding of CVD risk stratification and reduction strategies in HIV.
Literature
1.
Palella Jr FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27–34.PubMedCrossRef
2.
Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med. 2007;146(2):87–95.PubMed
3.
Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006;145(6):397–406.PubMed
4.
Dolan SE, Hadigan C, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr. 2005;39(1):44–54.PubMedCrossRef
5.
Saves M, Chene G, Ducimetiere P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis. 2003;37(2):292–8.PubMedCrossRef
6.
Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506–12.PubMedCrossRef
7.
• Lo J, Abbara S, Shturman L, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2010;24(2):243–53. A study which demonstrated in HIV+ men a higher prevalence of subclinical atherosclerosis versus non-HIV men matched on traditional CVD risk factors. Subclinical atherosclerosis was characterized via coronary computed tomography angiography as presence of coronary plaque.PubMedCrossRef
8.
9.
Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993–2003.PubMedCrossRef
10.
El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283–96.PubMedCrossRef
11.
• Oliviero U, Bonadies G, Apuzzi V, et al. Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis. 2009;204(2):586–9. A study which demonstrated in HIV+ ART-naive subjects increased mean carotid IMT and impaired brachial FMD versus healthy control subjects matched on metabolic risk factors.PubMedCrossRef
12.
• Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23(9):1059–67. A study which demonstrated in HIV+ elite controllers increased mean carotid IMT versus non-HIV subjects even after retrospectively controlling for CVD risk factors.PubMedCrossRef
13.
14.
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43.PubMedCrossRef
15.
Packard RR, Lichtman AH, Libby P. Innate and adaptive immunity in atherosclerosis. Semin Immunopathol. 2009;31(1):5–22.PubMedCrossRef
16.
Koenen RR, Weber C. Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov. 2010;9(2):141–53.PubMedCrossRef
17.
Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317–25.PubMedCrossRef
18.
Park IW, Wang JF, Groopman JE. HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes. Blood. 2001;97(2):352–8.PubMedCrossRef
19.
Dhawan S, Puri RK, Kumar A, Duplan H, Masson JM, Aggarwal BB. Human immunodeficiency virus-1-tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells. Blood. 1997;90(4):1535–44.PubMed
20.
Liu K, Chi DS, Li C, Hall HK, Milhorn DM, Krishnaswamy G. HIV-1 Tat protein-induced VCAM-1 expression in human pulmonary artery endothelial cells and its signaling. Am J Physiol Lung Cell Mol Physiol. 2005;289(2):L252–60.PubMedCrossRef
21.
Cota-Gomez A, Flores NC, Cruz C, et al. The human immunodeficiency virus-1 Tat protein activates human umbilical vein endothelial cell E-selectin expression via an NF-kappa B-dependent mechanism. J Biol Chem. 2002;277(17):14390–9.PubMed
22.
Matzen K, Dirkx AE, Oude Egbrink MG, et al. HIV-1 Tat increases the adhesion of monocytes and T-cells to the endothelium in vitro and in vivo: implications for AIDS-associated vasculopathy. Virus Res. 2004;104(2):145–55.PubMedCrossRef
23.
Ren Z, Yao Q, Chen C. HIV-1 envelope glycoprotein 120 increases intercellular adhesion molecule-1 expression by human endothelial cells. Lab Invest. 2002;82(3):245–55.PubMedCrossRef
24.
Takano Y, Shimokado K, Hata Y, Yoshida M. HIV envelope protein gp120-triggered CD4+ T-cell adhesion to vascular endothelium is regulated via CD4 and CXCR4 receptors. Biochim Biophys Acta. 2007;1772(5):549–55.PubMedCrossRef
25.
Conaldi PG, Serra C, Dolei A, et al. Productive HIV-1 infection of human vascular endothelial cells requires cell proliferation and is stimulated by combined treatment with interleukin-1 beta plus tumor necrosis factor-alpha. J Med Virol. 1995;47(4):355–63.PubMedCrossRef
26.
Park IW, Ullrich CK, Schoenberger E, Ganju RK, Groopman JE. HIV-1 Tat induces microvascular endothelial apoptosis through caspase activation. J Immunol. 2001;167(5):2766–71.PubMed
27.
Huang MB, Khan M, Garcia-Barrio M, Powell M, Bond VC. Apoptotic effects in primary human umbilical vein endothelial cell cultures caused by exposure to virion-associated and cell membrane-associated HIV-1 gp120. J Acquir Immune Defic Syndr. 2001;27(3):213–21.PubMedCrossRef
28.
Westhorpe CL, Zhou J, Webster NL, et al. Effects of HIV-1 infection in vitro on transendothelial migration by monocytes and monocyte-derived macrophages. J Leukoc Biol. 2009;85(6):1027–35.PubMedCrossRef
29.
Percario Z, Olivetta E, Fiorucci G, et al. Human immunodeficiency virus type 1 (HIV-1) Nef activates STAT3 in primary human monocyte/macrophages through the release of soluble factors: involvement of Nef domains interacting with the cell endocytotic machinery. J Leukoc Biol. 2003;74(5):821–32.PubMedCrossRef
30.
Olivetta E, Percario Z, Fiorucci G, et al. HIV-1 Nef induces the release of inflammatory factors from human monocyte/macrophages: involvement of Nef endocytotic signals and NF-kappa B activation. J Immunol. 2003;170(4):1716–27.PubMed
31.
Schlitt A, Heine GH, Blankenberg S, et al. CD14 + CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb Haemost. 2004;92(2):419–24.PubMed
32.
Frostegard J, Ulfgren AK, Nyberg P, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999;145(1):33–43.PubMedCrossRef
33.
Benagiano M, Azzurri A, Ciervo A, et al. T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci U S A. 2003;100(11):6658–63.PubMedCrossRef
34.
Thieblemont N, Weiss L, Sadeghi HM, Estcourt C, Haeffner-Cavaillon N. CD14lowCD16high: a cytokine-producing monocyte subset which expands during human immunodeficiency virus infection. Eur J Immunol. 1995;25(12):3418–24.PubMedCrossRef
35.
Palmer S, Hamblin AS. Increased CD11/CD18 expression on the peripheral blood leucocytes of patients with HIV disease: relationship to disease severity. Clin Exp Immunol. 1993;93(3):344–9.PubMedCrossRef
36.
Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008;197(1):126–33.PubMedCrossRef
37.
Baker J, Ayenew W, Quick H, et al. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis. 2010;201(2):285–92.PubMedCrossRef
38.
Ross AC, Armentrout R, O’Riordan MA, et al. Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr. 2008;49(5):499–506.PubMedCrossRef
39.
Schillaci G, De Socio GV, Pucci G, et al. Aortic stiffness in untreated adult patients with human immunodeficiency virus infection. Hypertension. 2008;52(2):308–13.PubMedCrossRef
40.
Baker JV, Duprez D, Rapkin J, et al. Untreated HIV infection and large and small artery elasticity. J Acquir Immune Defic Syndr. 2009;52(1):25–31.PubMedCrossRef
41.
Papasavvas E, Pistilli M, Reynolds G, et al. Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients. AIDS. 2009;23(3):369–75.PubMedCrossRef
42.
Tebas P, Henry WK, Matining R, et al. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS One. 2008;3(4):e2021.PubMedCrossRef
43.
Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203.PubMedCrossRef
44.
Papasavvas E, Azzoni L, Pistilli M, et al. Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resumption of antiretroviral therapy. AIDS. 2008;22(10):1153–61.PubMedCrossRef
45.
Francisci D, Giannini S, Baldelli F, et al. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS. 2009;23(5):589–96.PubMedCrossRef
46.
Calmy A, Gayet-Ageron A, Montecucco F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS. 2009;23(8):929–39.PubMedCrossRef
47.
• Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol. 2008;52(7):569–76. A study which demonstrated that the initiation of any of 3 ART regimens in ART-naive HIV+ subjects improved brachial FMD.PubMedCrossRef
48.
Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74(5):1045–52.PubMedCrossRef
49.
Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289(22):2978–82.PubMedCrossRef
50.
Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352(1):48–62.PubMedCrossRef
51.
Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004;45(7):1169–96.PubMedCrossRef
52.
Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011;8(4):222–32.PubMedCrossRef
53.
Mujawar Z, Rose H, Morrow MP, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol. 2006;4(11):e365.PubMedCrossRef
54.
Cui HL, Grant A, Mukhamedova N, et al. HIV-1 Nef mobilizes lipid rafts in macrophages through a pathway that competes with ABCA1-dependent cholesterol efflux. J Lipid Res. 2012;53(4):696–708.PubMedCrossRef
55.
Rose H, Hoy J, Woolley I, et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis. 2008;199(1):79–86.PubMedCrossRef
56.
Kelesidis T, Yang OO, Currier JS, Navab K, Fogelman AM, Navab M. HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL. Lipids Health Dis. 2011;10:35.PubMedCrossRef
57.
Duong M, Petit JM, Martha B, et al. Concentration of circulating oxidized LDL in HIV-infected patients treated with antiretroviral agents: relation to HIV-related lipodystrophy. HIV Clin Trials. 2006;7(2):41–7.PubMedCrossRef
58.
• Baker JV, Neuhaus J, Duprez D, et al. Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. AIDS. 2011;25(17):2133–42. A study which demonstrated that ART-naive HIV+ subjects randomized to ART had higher HDL-P and ApoA1 than those randomized to drug conservation. PubMedCrossRef
59.
• Kaplan RC, Sinclair E, Landay AL, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis. 2011;203(4):452–63. A study demonstrating that makers of T cell activation and senescence are higher in HIV+ women than in non-HIV controls. Among HIV+ women, T-cell activation and senescence markers correlated closely with prevalence of subclinical atherosclerosis on carotid ultrasound.PubMedCrossRef
60.
• Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis. 2011;204(8):1227–36. A study demonstrating that sCD163—a marker of monocyte/macrophage activation—is higher among ART-treated HIV+ men than non-HIV controls. Among HIV+ men, sCD163 correlates with segments of noncalcified plaque on computed tomography coronary angiography.PubMedCrossRef
61.
• Parra S, Marsillach J, Aragones G, et al. Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients. J Infect Dis. 2010;201(4):627–34. A study demonstrating that among HIV+ subjects, haplotype H7 of the PON1 gene (whose protein product is an HDL-associated antioxidant enzyme) associated with lower rates of subclinical atherosclerosis on carotid and femoral ultrasound.PubMedCrossRef
62.
• Shrestha S, Irvin MR, Taylor KD, et al. A genome-wide association study of carotid atherosclerosis in HIV-infected men. AIDS. 2010;24(4):583–92. A genome-wide association study showing that among HIV+ subjects, SNP’s in the RYR3 gene are associated with subclinical atherosclerosis on carotid ultrasound.PubMedCrossRef
63.
• Gupta SK, Johnson RM, Mather KJ, et al. Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: a pilot study. AIDS. 2010;24(9):1377–80. A pilot single-arm study demonstrating that treatment of untreated HIV+ subjects with the TNF-α antagonist pentoxifylline improved brachial FMD.PubMedCrossRef
Metadata
Title
HIV-Specific Immune Dysregulation and Atherosclerosis
Authors
Markella V. Zanni
Steven K. Grinspoon
Publication date
01-09-2012
Publisher
Current Science Inc.
Published in
Current HIV/AIDS Reports / Issue 3/2012
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-012-0123-y

Other articles of this Issue 3/2012

Current HIV/AIDS Reports 3/2012 Go to the issue

Metabolic Complications and Comorbidity (JM Kilby, Section Editor)

Osteoporosis and Bone Health in HIV

Metabolic Complications and Comorbidity (JM Kilby, Section Editor)

The Burden of Diabetes and Hyperlipidemia in Treated HIV Infection and Approaches for Cardiometabolic Care

Co-infections (C Benson, Section Editor)

Management of the Immune Reconstitution Inflammatory Syndrome

Metabolic Complications and Comorbidity (JM Kilby, Section Editor)

Smoking and HIV: Prevalence, Health Risks, and Cessation Strategies

Co-infections (C Benson, Section Editor)

New Insights in the Prevention, Diagnosis, and Treatment of Cryptococcal Meningitis

Co-infections (C Benson, Section Editor)

Human Papillomavirus Vaccines: Where Do They Fit in HIV-Infected Individuals?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits